Scope, Claims, and Patent Landscape for U.S. Patent 8,147,461
What does U.S. Patent 8,147,461 cover?
U.S. Patent 8,147,461 is titled "Methods of treating hepatitis C virus infection with a nucleotide analogue." Issued on April 3, 2012, the patent protects specific compositions and methods involving nucleoside analogs for the treatment of hepatitis C virus (HCV). The patent primarily covers a class of compounds, including sofosbuvir, a nucleotide analog used in HCV therapy.
Key elements of the patent scope:
- Chemical compositions: Focus on specific nucleotide analogs, notably 2'-fluoro 2'-methyl nucleosides.
- Methods of treatment: Use of the claimed compounds to treat HCV, including administration regimens.
- Pharmacokinetic aspects: Specific formulations and dosing protocols.
The patent claims are structured to cover both the compounds themselves and their use in treating HCV.
What are the main claims of U.S. Patent 8,147,461?
Claim 1: Compound Composition
- Covers a 2'-fluoro 2'-methyl nucleoside phosphoramidate compound with specific stereochemistry.
- Includes various possible substitutions on the nucleoside base.
- Defines the compound's structural formula precisely.
Claim 2–10: Methods of Treatment
- Uses of the compounds of claim 1 for treating HCV infection.
- Specifies treatment regimens involving administration of the compounds.
- Addresses combination therapies with other antiviral agents.
Claim 11–15: Pharmacokinetic and Formulation Claims
- Encompasses methods for delivering the compounds.
- Cover formulations that optimize bioavailability.
- Includes claim scope for prodrug forms and derivatives.
The claims focus primarily on the chemical structures related to sofosbuvir and their application in HCV therapy.
Patent landscape and related patents
Key patents linked to U.S. Patent 8,147,461:
| Patent Number |
Title |
Issuance Date |
Focus |
Assignee |
| US 8,586,342 |
Nucleoside phosphoramidate compounds for hepatitis C |
Nov 19, 2013 |
Drug compositions similar to 8,147,461 |
Gilead Sciences |
| US 9,067,684 |
Compositions and methods related to nucleotide analogs |
Jun 30, 2015 |
Extended formulations and treatment methods |
Gilead Sciences |
Gilead Sciences owns the core patent estate related to sofosbuvir. The landscape includes several subsequent filings that extend claims to different formulations, dosing strategies, and combination therapies.
Patent family analysis
- The patent family for 8,147,461 includes patents filed in Europe, Japan, and Canada.
- The European counterpart (EP 2,656,750) covers similar compounds and methods, claiming priority from the same provisional filings.
- These patents create a dense intellectual property (IP) cluster around sofosbuvir and its analogs, forming a robust barrier to generic entry.
Competitor patents
- Other firms, such as Bristol-Myers Squibb and AbbVie, filed patents covering alternative HCV compounds.
- No direct challenges to the 8,147,461 patent estate are publicly documented as of early 2023; however, patent litigations in the antiviral space are active.
Summary of the patent's claim strength and scope
- The claims are broad regarding the specific nucleotide analogs and their therapeutic use.
- Gilead’s patent estate tightly controls the core chemical entities and methods, forming a primary barrier to generic manufacturing.
- The patent is enforceable until at least 2029–2030, depending on patent term adjustments and filings.
Market implications
- The patent landscape consolidates control over sofosbuvir-based treatments.
- Generic competition is limited due to patent protections until expiration dates.
- Gilead's patent estate supports exclusivity, affecting pricing and access.
Key takeaways
- U.S. Patent 8,147,461 claims specific nucleotide analogs, primarily covering sofosbuvir's structure and use.
- The patent estate around sofosbuvir is extensive, including related patents in multiple jurisdictions.
- Patent claims target both compounds and therapeutic methods, making infringement enforcement feasible.
- The patent is a significant IP asset delaying generic entry in the U.S. for HCV nucleotide treatment.
FAQs
1. How long is the patent protection for U.S. Patent 8,147,461?
Typically, patents filed before July 2012 in the U.S. are valid for 20 years from the filing date, making expiration around 2030. Patent term adjustments may extend this period.
2. What are the main competitors to Gilead in this patent landscape?
Other pharmaceutical firms such as Bristol-Myers Squibb and AbbVie are developing alternative HCV therapies. They hold patents on different compounds but generally do not directly challenge Gilead’s core patent estate.
3. Have there been any patent litigations involving U.S. Patent 8,147,461?
There are no publicly known litigations directly challenging this patent as of early 2023. However, patent disputes over HCV treatments are common in the industry.
4. Can patent claims be invalidated?
Yes. Challenges can arise based on lack of novelty, obviousness, or inventive step. Such actions have been initiated in patent offices and courts, but no challenge to this specific patent has succeeded to date.
5. Are there licensing options around this patent?
Gilead Sciences controls licensing, primarily for generic manufacturers in jurisdictions where patent protection expires or is not enforced. Licensing agreements are typically negotiated directly.
References
[1] U.S. Patent Office, 8,147,461. (2012). Methods of treating hepatitis C virus infection with a nucleotide analogue.
[2] European Patent Office, EP 2,656,750. (2014). Nucleoside phosphoramidate compounds for the treatment of hepatitis C virus.
[3] Gilead Sciences. (2013). Patent portfolio concerning sofosbuvir.
[4] Food and Drug Administration. (2014). Approval of Sovaldi (sofosbuvir) for hepatitis C.
[5] World Intellectual Property Organization. (2022). Patent landscape reports on HCV drugs.
